A Multicenter, Randomized, Double-Blind, Double-Dummy Comparative Trial of Azithromycin Sustained Release Versus 3-Day Azithromycin for the Treatment of Strep Throat in Adolescents and Adults
Public ClinicalTrials.gov record NCT00644293. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Double-Blind, Double-Dummy Comparative Trial of Azithromycin SR Versus Three-Day Azithromycin for the Treatment of Group A β-Hemolytic Streptococcal Pharyngitis/Tonsillitis in Adolescents and Adults
Study identification
- NCT ID
- NCT00644293
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Pfizer
- Industry
- Enrollment
- 598 participants
Conditions and interventions
Conditions
Interventions
- azithromycin (Zithromax) Drug
- azithromycin SR Drug
- placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 13 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2002
- Primary completion
- Not listed
- Completion
- Mar 31, 2004
- Last update posted
- Jun 7, 2011
2003 – 2004
United States locations
- U.S. sites
- 16
- U.S. states
- 7
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Clearwater | Florida | 33761 | — |
| Pfizer Investigational Site | Boise | Idaho | 83651 | — |
| Pfizer Investigational Site | Boise | Idaho | 83703 | — |
| Pfizer Investigational Site | Boise | Idaho | 83704 | — |
| Pfizer Investigational Site | Boise | Idaho | 83706 | — |
| Pfizer Investigational Site | Boise | Idaho | 83709 | — |
| Pfizer Investigational Site | Meridian | Idaho | 83642 | — |
| Pfizer Investigational Site | Nampa | Idaho | 83651 | — |
| Pfizer Investigational Site | Omaha | Nebraska | 68144 | — |
| Pfizer Investigational Site | Hickory | North Carolina | 28601 | — |
| Pfizer Investigational Site | Eugene | Oregon | 97404 | — |
| Pfizer Investigational Site | Bensalem | Pennsylvania | 19020 | — |
| Pfizer Investigational Site | Harleysville | Pennsylvania | 19438 | — |
| Pfizer Investigational Site | Salt Lake City | Utah | 84109 | — |
| Pfizer Investigational Site | Salt Lake City | Utah | 84121 | — |
| Pfizer Investigational Site | West Jordan | Utah | 84088 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 43 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00644293, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 7, 2011 · Synced Apr 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00644293 live on ClinicalTrials.gov.